These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33049114)

  • 1. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
    Wessels AM; Lines C; Stern RA; Kost J; Voss T; Mozley LH; Furtek C; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; Dupre N; Randolph C; Michelson D; Andersen SW; Shering C; Sims JR; Egan MF
    Alzheimers Dement; 2020 Nov; 16(11):1483-1492. PubMed ID: 33049114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
    Sur C; Kost J; Scott D; Adamczuk K; Fox NC; Cummings JL; Tariot PN; Aisen PS; Vellas B; Voss T; Mahoney E; Mukai Y; Kennedy ME; Lines C; Michelson D; Egan MF
    Brain; 2020 Dec; 143(12):3816-3826. PubMed ID: 33253354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
    Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
    N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
    Wessels AM; Tariot PN; Zimmer JA; Selzler KJ; Bragg SM; Andersen SW; Landry J; Krull JH; Downing AM; Willis BA; Shcherbinin S; Mullen J; Barker P; Schumi J; Shering C; Matthews BR; Stern RA; Vellas B; Cohen S; MacSweeney E; Boada M; Sims JR
    JAMA Neurol; 2020 Feb; 77(2):199-209. PubMed ID: 31764959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
    [No Abstract]   [Full Text] [Related]  

  • 7. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.
    Egan MF; Mukai Y; Voss T; Kost J; Stone J; Furtek C; Mahoney E; Cummings JL; Tariot PN; Aisen PS; Vellas B; Lines C; Michelson D
    Alzheimers Res Ther; 2019 Aug; 11(1):68. PubMed ID: 31387606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer's Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy.
    Sergott RC; Raji A; Kost J; Sur C; Jackson S; Locco A; Patel A; Furtek C; Mattson B; Egan MF
    J Alzheimers Dis; 2021; 79(1):275-287. PubMed ID: 33252075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat.
    Querol-Vilaseca M; Sirisi S; Molina-Porcel L; Molina B; Pegueroles J; Ferrer-Raventós P; Nuñez-Llaves R; Dols-Icardo O; Balasa M; Iulita MF; Blesa R; Belbin O; Clarimon J; Fortea J; Gelpi E; Sánchez-Valle R; Lleó A
    Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12781. PubMed ID: 34825396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Merck ends trial of potential Alzheimer's drug verubecestat.
    Hawkes N
    BMJ; 2017 Feb; 356():j845. PubMed ID: 28202490
    [No Abstract]   [Full Text] [Related]  

  • 12. Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions.
    Voss T; Kost J; Mercer SP; Furtek C; Randolph C; Lines C; Egan MF; Cummings JL
    J Alzheimers Dis; 2023; 92(1):341-348. PubMed ID: 36744336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-secretase inhibitors for Alzheimer's disease: heading in the wrong direction?
    Selkoe D
    Lancet Neurol; 2019 Jul; 18(7):624-626. PubMed ID: 31202466
    [No Abstract]   [Full Text] [Related]  

  • 14. Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.
    Evin G
    BioDrugs; 2016 Jun; 30(3):173-94. PubMed ID: 27023706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814).
    Sims JR; Selzler KJ; Downing AM; Willis BA; Aluise CD; Zimmer J; Bragg S; Andersen S; Ayan-Oshodi M; Liffick E; Eads J; Wessels AM; Monk S; Schumi J; Mullen J
    J Prev Alzheimers Dis; 2017; 4(4):247-254. PubMed ID: 29181490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BACE inhibitors in clinical development for the treatment of Alzheimer's disease.
    Panza F; Lozupone M; Solfrizzi V; Sardone R; Piccininni C; Dibello V; Stallone R; Giannelli G; Bellomo A; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP
    Expert Rev Neurother; 2018 Nov; 18(11):847-857. PubMed ID: 30277096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BACE inhibitor bust in Alzheimer trial.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248932
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
    Qu L; Ji L; Wang C; Luo H; Li S; Peng W; Yin F; Lu D; Liu X; Kong L; Wang X
    Eur J Med Chem; 2021 Jul; 219():113441. PubMed ID: 33862517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.